Hubei Gedian Humanwell Pharmaceutical Abiraterone Acetate Hubei Gedian Humanwell Pharmaceutical Abiraterone Acetate

X

Find Radio Compass News for Abiraterone Acetate

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

JP

0

Other Listed Suppliers

SERVICES
left grey arrow
right gray arrow
  • TABLET;ORAL - 250MG
  • TABLET;ORAL - 500MG

https://www.businesswire.com/news/home/20231003205808/en

BUSINESSWIRE
03 Oct 2023

https://www.businesswire.com/news/home/20230824404671/en

BUSINESSWIRE
24 Aug 2023

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-brca-mutated-metastatic-castration?utm_medium=email&utm_source=govdelivery#:~:text=On%20August%2011%2C%202023%2C%20the,as%20determined%20by%20an%20FDA%2D

FDA
12 Aug 2023

https://www.ema.europa.eu/en/documents/overview/abiraterone-mylan-epar-medicine-overview_en.pdf

EMA
18 Jul 2023

https://www.biospace.com/article/releases/health-canada-approves-lynparza-in-combination-with-abiraterone-and-prednisone-or-prednisolone-for-patients-with-brca-mutated-metastatic-castration-resistant-prostate-cancer/

BIOSPACE
14 Jul 2023

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration#:~:text=On%20May%2031%2C%202023%2C%20the,mCRPC)%2C%20as%20determined%20by%20an

FDA
01 Jun 2023

https://www.businesswire.com/news/home/20230601005453/en

BUSINESSWIRE
01 Jun 2023

https://www.business-standard.com/world-news/us-fda-panel-backs-restricted-use-of-astrazeneca-s-prostate-cancer-drug-123050100632_1.html

BUSINESS-STANDARD
02 May 2023

https://www.fiercepharma.com/pharma/astrazeneca-lynparza-combo-fda-advisory-committee-prostate-cancer-vote

Angus Liu FIERCE PHARMA
29 Apr 2023

https://www.businesswire.com/news/home/20230428005574/en

BUSINESSWIRE
28 Apr 2023

https://endpts.com/janssen-gets-priority-review-for-prostate-cancer-combo-immunogen-reports-q1-elahere-sales/

Tyler Patchen ENDPTS
28 Apr 2023

https://www.europeanpharmaceuticalreview.com/news/180797/mhra-approves-prostate-cancer-combination-therapy/

EUROPEAN PHARMACEUTICAL REVIEW
21 Mar 2023

https://www.astrazeneca.com/media-centre/press-releases/2023/overall-survival-analysis-of-the-lynparza-propel-phase-iii-trial-in-metastatic-castration-resistant-prostate-cancer.html

PRESS RELEASE
17 Feb 2023

https://www.globenewswire.com/news-release/2023/02/16/2609811/0/en/Janssen-Presents-Updated-Data-Demonstrating-Improved-Outcomes-from-the-Use-of-Niraparib-in-Combination-with-Abiraterone-Acetate-Plus-Prednisone-as-a-First-Line-Therapy-in-Patients-.html

GLOBENEWSWIRE
16 Feb 2023

https://www.prnewswire.com/news-releases/tavanta-therapeutics-announces-positive-top-line-results-from-pivotal-phase-3-trial-of-tavt-45-for-the-treatment-of-metastatic-prostate-cancer-301714563.html

PR NEWSWIRE
05 Jan 2023

https://www.merck.com/news/lynparza-olaparib-in-combination-with-abiraterone-and-prednisone-or-prednisolone-approved-in-the-eu-as-treatment-for-certain-patients-with-metastatic-castration-resistant-prostate-cancer/

PRESS RELEASE
21 Dec 2022

https://www.businesswire.com/news/home/20221221005090/en

BUSINESSWIRE
21 Dec 2022

https://www.fiercepharma.com/pharma/fda-needs-3-more-months-review-astrazeneca-and-mercks-lynparza-first-line-prostate-cancer

Kevin Dunleavy FIERCEPHARMA
16 Dec 2022

http://pharmabiz.com/NewsDetails.aspx?aid=154468&sid=2

PHARMABIZ
15 Nov 2022

https://www.globenewswire.com/news-release/2022/09/10/2513543/0/en/POINT-Biopharma-Provides-Updated-Efficacy-and-Safety-Data-from-the-Lead-In-Cohort-of-the-Phase-3-SPLASH-Trial-in-mCRPC-at-ESMO-Congress-2022.html

GLOBENEWSWIRE
09 Sep 2022

https://www.thepharmaletter.com/article/lynparza-combo-accepted-by-fda-for-priority-review

THEPHARMALETTER
17 Aug 2022

https://www.businesswire.com/news/home/20220803005101/en

BUSINESSWIRE
03 Aug 2022

https://www.europeanpharmaceuticalreview.com/news/172552/improved-outcome-for-prostate-cancer-patients-in-phase-iii-propel-trial/

EUROPEANPHARMACEUTICALREVIEW
22 Jun 2022

https://www.businesswire.com/news/home/20220621006021/en

BUSINESSWIRE
21 Jun 2022

https://www.businesswire.com/news/home/20220428005637/en

BUSINESSWIRE
28 Apr 2022

https://endpts.com/astrazeneca-merck-come-out-of-asco-gu-with-a-big-win-over-jj-in-battle-over-prostate-cancer-franchises/

John Carroll ENDPTS
15 Feb 2022

https://www.businesswire.com/news/home/20220214005576/en

BUSINESSWIRE
14 Feb 2022

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215947

FDA
05 Jan 2022

https://www.clinicaltrialsarena.com/news/abiraterone-mortality-prostate-cancer/

CLINICALTRIALSARENA
24 Dec 2021

https://www.targetedonc.com/view/overall-survival-in-high-risk-nonmetastatic-prostate-cancer-improved-with-abiraterone-acetate-and-prednisolone-based-treatment

TARGETDONC
21 Sep 2021

https://www.icr.ac.uk/news-archive/abiraterone-keeps-men-with-prostate-cancer-at-risk-of-spreading-alive-for-longer

ICR
19 Sep 2021

https://www.businesswire.com/news/home/20210918005010/en

BUSINESSWIRE
18 Sep 2021

https://www.businesswire.com/news/home/20210914005365/en

BUSINESSWIRE
14 Sep 2021